Summary: As a Dividend King with six decades of dividend growth to its credit and
Summary: Under current market conditions, our view is that playing defensive is more important than
Summary: The third quarter of 2023 showed excellent results, which also exceeded our expectations. Carvykti
Summary: Johnson & Johnson, America’s oldest and bluest chip corporation, is facing significant recurring litigation
Summary: Johnson & Johnson reported Q3 earnings with a 6.8% surge in sales, reaching $21.4
Summary: Johnson & Johnson is a defensive pick with a renewed focus on its pharmaceutical
Summary: Johnson & Johnson will announce its Q3 earnings on October 17th, with analysts expecting
Summary: J&J’s stock fell steeply following its share exchange offer for Kenvue stock, but dip
Summary: Johnson & Johnson reported solid second quarter results – with MedTech reporting double-digit growth
Summary: Johnson & Johnson’s strategic transformation, marked by the split-off of its consumer health division,